In patients with sickle cell disease, what is the typical level of Hemoglobin A?

Prepare for the NBME Form 15 Test with our tailored quiz featuring flashcards and multiple-choice questions, each with hints and detailed explanations. Achieve success with our comprehensive study materials!

Multiple Choice

In patients with sickle cell disease, what is the typical level of Hemoglobin A?

Explanation:
In patients with sickle cell disease, the typical level of Hemoglobin A is decreased. Sickle cell disease is a genetic disorder caused by a mutation in the gene that encodes the beta chain of hemoglobin, resulting in the production of Hemoglobin S (HbS) instead of the normal Hemoglobin A (HbA). As a result, individuals with sickle cell disease primarily produce HbS, leading to a lower concentration of HbA. In these patients, the presence of HbA can vary based on factors such as the degree of co-inheritance of other hemoglobinopathies like hereditary persistence of fetal hemoglobin which can influence the overall hemoglobin profile. However, in the classical presentation of sickle cell disease, the level of Hemoglobin A is notably decreased, typically ranging from 0-20% depending on the individual's specific genetic makeup and any therapeutic interventions they might be receiving.

In patients with sickle cell disease, the typical level of Hemoglobin A is decreased. Sickle cell disease is a genetic disorder caused by a mutation in the gene that encodes the beta chain of hemoglobin, resulting in the production of Hemoglobin S (HbS) instead of the normal Hemoglobin A (HbA).

As a result, individuals with sickle cell disease primarily produce HbS, leading to a lower concentration of HbA. In these patients, the presence of HbA can vary based on factors such as the degree of co-inheritance of other hemoglobinopathies like hereditary persistence of fetal hemoglobin which can influence the overall hemoglobin profile. However, in the classical presentation of sickle cell disease, the level of Hemoglobin A is notably decreased, typically ranging from 0-20% depending on the individual's specific genetic makeup and any therapeutic interventions they might be receiving.

Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy